Checked.be · Company dossierhttps://checked.be/en/c/solidpharma-0826168103 · as of 20-11-2026
Solidpharma
ActivePrivate limited company · founded 2010 · active for 16 yearsHeistraat 16, 9052 GhentKBO/BCE: BE 0826.168.103subsidiary of Name hiddenVisible after signing in
Save to list
With a free account you keep companies in your own lists to find and compare them later.
1 directorName after signing inVisible after signing in
Owners
100%Name hiddenVisible after signing in
Documentsfilings and deeds
03-01-20263 days late
2025abbreviated format
Gross margin from €824,440 to €1.1mResult from €14,558 to €163,718Staff from 6.9 FTE to 6 FTEEquity from €569,453 to €733,170Cash from €154,621 to €296,454
Six of the last ten came late. The 2021 accounts came in latest, 31 days after the end of the period.
Checked score
Checked score
The higher the Checked score (0 to 100), the smaller the chance that the company goes bankrupt within twelve months. That chance sets the band, from Critical to Excellent, and within the band how the company does against its sector peers counts too. With a low score, agree a shorter payment term, an advance or security.
XXVisible after signing in
HiddenVisible after signing in
Bankruptcy probability within 12 months
Bankruptcy probability
It is the chance that the company goes bankrupt within twelve months, estimated from the registers, the annual accounts and the Belgian Official Gazette. At 0.2%, about 2 in 1,000 comparable companies go bankrupt. The higher it is, the shorter the payment term to agree.
XXVisible after signing in
Financial strength
Financial strength
Financial strength measures the balance sheet and the results with three figures out of 100 from the latest annual accounts: solvency, liquidity and profitability. It does not directly set the Checked score's band. How the company does against its sector peers on these and on growth does count for its place within the band.
XXVisible after signing in
XXVisible after signing in
XXVisible after signing in
Score breakdown
Visible after signing inVisible after signing in
Comparable companies, two years later
In July 2024, 34,728 companies had the same profile as Solidpharma has now. Each dot stands for 87 companies, two years later.
95.2%
were still trading
4.0%
stopped another way
0.7%
went bankrupt
Micro
10 to 20 years old
solvency 30% or more
a profit of 5% of the balance sheet or more
Test of the method
The method was tested on the 497,994 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
The companies in ten equal groups, from the lowest to the highest expected share
Group
Expected
Actual
1
0.2%
0.2%
2
0.3%
0.5%
3
0.5%
0.6%
4
0.7%
0.8%
5
0.9%
0.9%
6
1.3%
1.5%
7
1.6%
1.8%
8
1.8%
1.8%
9
2.9%
3.1%
10
5.6%
6.1%
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 34,728 companies, not a prediction for Solidpharma. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit verdict
The credit verdict says how much credit you can give the company on open account. “Acceptable” means normal terms, “With conditions” means limiting the amount or the term. “Not advised” means asking for payment up front.
Visible after signing inVisible after signing in
Credit check for an amount and term of your choice
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Hidden signalVisible after signing in
Signal visible after signing inVisible after signing in
Signal hidden, visible after signing inVisible after signing in
Hidden signalVisible after signing in
Signal visible after signing inVisible after signing in
Signal hidden, visible after signing inVisible after signing in
Board and ownership
Hidden nameVisible after signing in
Director, Name after signing inVisible after signing in, since 14-07-2020
Name hiddenVisible after signing in 100%score XXVisible after signing inequity €2.0m (2025) · annual accounts 2025 of Name after signing inVisible after signing in
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0826168103
Legal-form change
General meeting of 29-12-2022 · Gazette deed
Registered office moved from Affligem to Ghent
The registered office moved from Krokussenlaan 20, 1790 Affligem to Heistraat 16, 9052 Gent · Hidden nameVisible after signing in (director) and Name after signing inVisible after signing in (director) resign · Name hiddenVisible after signing in appointed as director · General meeting of 14-07-2020 · Gazette deed
Company renamed to SOLIDPHARMA
Capital decrease of €45,400 to €18,600 · The capital fell from €64,000 to €18,600 · General meeting of 20-12-2017 · Gazette deed
Sector peers are the companies with the same activity (NACE code) and, where stated, the same size, that the company is compared with. A percentile says how many of them do worse.
These companies have the same main activity as Solidpharma: retail sale of medical and orthopaedic goods, excluding prescription glasses and lenses (NACE 47741). They are comparable in size and age: total assets between €1.6m and €3.1m, founded between 2006 and 2012.
According to the KBO register, the main activity is retail sale of medical and orthopaedic goods, excluding prescription glasses and lenses (NACE 47741).
What is the legal form of Solidpharma?
Solidpharma is a private limited company (BV).
When was Solidpharma founded?
Solidpharma was founded on 19-05-2010.
Is Solidpharma still active?
Yes, Solidpharma is an active enterprise in the KBO register.
How many employees does Solidpharma have?
Solidpharma had an average of 6 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
What is the turnover of Solidpharma?
The turnover in financial year 2025 is about €3.1m. This figure is estimated from the gross margin of €1.1m and 31 comparable companies (NACE 477). It probably lies between €2.2m and €4.3m.
Is Solidpharma profitable?
In financial year 2025, Solidpharma made a profit of €163,718.
Where can I find the annual accounts of Solidpharma?
Solidpharma filed 14 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of Solidpharma due?
Solidpharma must file the annual accounts for financial year 2026 by 31-12-2026.Timeline